肌层浸润性膀胱癌新辅助化疗后延迟根治性膀胱切除术与不良生存结局相关
该研究纳入1999年至2015年间接受新辅助化疗(NAC)及根治性膀胱切除术(RC)的226例cT2-T4N0M0膀胱癌患者,评估末次NAC周期至RC的时间(TTC)与生存的关系。中位TTC为7.57周,TTC>10周组的总死亡率无事件生存率和癌症特异性死亡率无事件生存率均显著低于TTC≤10周组。校正年龄、性别、病理膀胱外侵犯及淋巴结状态后,TTC与总死亡风险(p=0.027)和癌症特异性死亡风险(p=0.004)独立相关。
要点
- NAC后TTC>10周与更差的总生存和癌症特异性生存相关。
- Charlson合并症指数≥1的患者TTC更长(p=0.027)。
- 校正混杂因素后TTC仍独立与总死亡和癌症特异性死亡风险相关。
核心结论
- NAC后TTC>10周与MIBC患者的不良生存相关。
- Charlson合并症指数较高的患者更可能出现TTC延长。
研究设计与样本
- 研究队列包含1999年至2015年间接受NAC和RC治疗的226例cT2-T4N0M0膀胱癌患者。
- 采用Kaplan-Meier法按TTC分组估计总死亡率(OM)和癌症特异性死亡率(CSM)。
- 采用多变量Cox回归分析评估与OM和CSM相关的因素。
主要发现
- 中位TTC为7.57周(四分位距5.2-10.8周)。
- Charlson合并症指数≥1的患者TTC长于评分<1者(p=0.027)。
- TTC>10周组的总死亡率无事件率显著低于TTC≤10周组(p=0.003)。
- TTC>10周组的癌症特异性死亡率无事件率显著低于TTC≤10周组(p<0.001)。
- 校正年龄、性别、病理膀胱外侵犯及淋巴结状态后,TTC与更高的OM风险(p=0.027)和CSM风险(p=0.004)独立相关。
临床怎么用
- 作者认为应努力缩短术前化疗后的TTC。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delaying radical cystectomy (RC) after a diagnosis of muscle-invasive bladder cancer (MIBC) has been associated with adverse survival. However, data are lacking regarding the impact of RC delay in patients receiving neoadjuvant chemotherapy (NAC). OBJECTIVES: To assess whether the time from last cycle of NAC to RC (time to cystectomy, TTC) is associated with survival among MIBC patients. DESIGN, SETTING, AND PARTICIPANTS: The study cohort comprised 226 patients treated with NAC and RC between 1999 and 2015 for cT2-T4N0M0 bladder cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Descriptive statistics were used to test the association between TTC and clinicopathologic variables. Overall mortality (OM) and cancer-specific mortality (CSM) were analyzed via Kaplan-Meier estimation according to TTC. We assessed factors associated with OM and CSM using multivariable Cox regression analyses. RESULTS AND LIMITATIONS: The median TTC was 7.57wk (interquartile range 5.2-10.8). Patients with a Charlson comorbidity index (CCI) ≥1 had a longer TTC than those with a score of <1 (p=0.027). The group with TTC >10wk had significantly lower OM-free (p=0.003) and CSM-free rates (p<0.001) than the group with TTC ≤10wk. TTC was independently associated with higher risk of OM (p=0.027) and CSM (p=0.004) after accounting for age, gender, pathologic extravesical disease, and nodal status. CONCLUSIONS: TTC of >10wk after NAC was associated with adverse survival among patients with MIBC. Patients with a higher CCI were more likely to have prolonged TTC. PATIENT SUMMARY: The impact of delaying radical cystectomy in patients who have received neoadjuvant chemotherapy (NAC) is unknown. In this study we assessed whether prolonged time to cystectomy (TTC) after NAC affects survival outcomes in patients with muscle-invasive bladder cancer. We found that TTC of >10wk was associated with adverse overall survival and cancer-specific survival, and attempts should be made to shorten TTC after preoperative chemotherapy.
引用
- Boeri L, Soligo M, Frank I, et al. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol. 2018. PMID: 31277775. doi:10.1016/j.euo.2018.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。